The Premise: Contemplate a world where eating meat derived from animals is a thing of the past. Ridiculous, you say. But during the past year, the field of cultured (or… Read more »
The News: Nasdaq-listed Chinese biotech BeiGene Ltd. (Beijing) has raised an astounding $903 million after pricing its secondary listing in Hong Kong–the first under new exchange rules–near the top of… Read more »
The News: GW Pharmaceuticals PLC (Cambridge UK), which focuses on the development of therapeutics using its cannabinoid product platform for a range of diseases, including autism, epilepsy and brain cancer, announced on Monday… Read more »
The News: Celgene Corp. (Summit NJ) plummeted 20% Thursday (October 26, 2017) to $99.99 after releasing third-quarter earnings. And it wasn’t so much third-quarter revenue, which was up 10% year over year,… Read more »
The News: Amgen Inc. (Thousand Oaks CA) has agreed to delay the US launch of its FDA-approved biosimilar version of AbbVie Inc.’s (North Chicago) Humira (adalimumab) until 2023, under a… Read more »
The News: Intra-Cellular Therapies Inc. (Nasdaq:ITCI) rocketed 41% over the past week to $15.70 on a positive regulatory update from the US Food and Drug Administration regarding its lumateperone treatment for schizophrenia…. Read more »
The News: Teva Pharmaceutical Industries Ltd., which has been without a permanent CEO for six months, plunged $11.74, or 36% last week, to $20.60–the most in almost two decades. The… Read more »
The News: Amgen Inc. (Thousand Oaks CA) and UCB SA (Brussels) no longer expect their experimental osteoporosis drug to win US approval this year after a higher rate of serious… Read more »
The News: Pfizer Inc. said Tuesday (May 2, 2017) that first-quarter sales declined 2% year-over-year to $12.8 billion, missing analyst estimates of $13.1 billion, with the company highlighting one less… Read more »
Among the top winners and losers in the healthcare sector last week, the following four were standouts and bear watching or acting upon, depending, as always, on one’s risk tolerance…. Read more »
